Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A serous adenocarcinoma that arises from the fallopian tube. It is usually a high grade invasive adenocarcinoma.
13 clinical trials registered. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 3 PHASE3, 6 PHASE2, 2 PHASE1. Research is sponsored by a mix of industry and academic institutions.
3 publications have been identified in PubMed for fallopian tube serous adenocarcinoma. Research spans Case Report / Case Series (100%).
Farrugia S (2025). [PMID: 41171797](https://pubmed.ncbi.nlm.nih.gov/41171797/). *Dermatol Online J*. [Case Report / Case Series]
Kanemura A (2024). [PMID: 39473877](https://pubmed.ncbi.nlm.nih.gov/39473877/). *Case Rep Obstet Gynecol*. [Case Report / Case Series]
Henning TJ (2024). [PMID: 39229302](https://pubmed.ncbi.nlm.nih.gov/39229302/). *Clin Case Rep*. [Case Report / Case Series]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:09 PM UTC